Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2013 1
2019 1
2020 2
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data.
Conrado DJ, Duvvuri S, Geerts H, Burton J, Biesdorf C, Ahamadi M, Macha S, Hather G, Francisco Morales J, Podichetty J, Nicholas T, Stephenson D, Trame M, Romero K, Corrigan B; Drug Development Tools in the Alzheimer Disease Continuum (DDT-AD) Working Group. Conrado DJ, et al. Among authors: biesdorf c. Clin Pharmacol Ther. 2020 Apr;107(4):796-805. doi: 10.1002/cpt.1782. Epub 2020 Mar 11. Clin Pharmacol Ther. 2020. PMID: 31955409 Review.
Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia.
Tahir SK, Calvo E, Carneiro BA, Yuda J, Shreenivas A, Jongen-Lavrencic M, Gort E, Ishizawa K, Morillo D, Biesdorf C, Smith M, Cheng D, Motwani M, Sharon D, Uziel T, Modi DA, Buchanan FG, Morgan-Lappe S, Medeiros BC, Phillips DC. Tahir SK, et al. Among authors: biesdorf c. Blood. 2023 Apr 27;141(17):2114-2126. doi: 10.1182/blood.2022017333. Blood. 2023. PMID: 36720090 Free PMC article.
Prophylactic evaluation of verubecestat on disease- and symptom-modifying effects in 5XFAD mice.
Oblak AL, Cope ZA, Quinney SK, Pandey RS, Biesdorf C, Masters AR, Onos KD, Haynes L, Keezer KJ, Meyer JA, Peters JS, Persohn SA, Bedwell AA, Eldridge K, Speedy R, Little G, Williams SP, Noarbe B, Obenaus A, Sasner M, Howell GR, Carter GW, Williams H, Lamb BT, Territo PR, Sukoff Rizzo SJ. Oblak AL, et al. Among authors: biesdorf c. Alzheimers Dement (N Y). 2022 Jul 14;8(1):e12317. doi: 10.1002/trc2.12317. eCollection 2022. Alzheimers Dement (N Y). 2022. PMID: 35846156 Free PMC article.
Pharmacokinetic, pharmacodynamic, and transcriptomic analysis of chronic levetiracetam treatment in 5XFAD mice: A MODEL-AD preclinical testing core study.
Onos KD, Quinney SK, Jones DR, Masters AR, Pandey R, Keezer KJ, Biesdorf C, Metzger IF, Meyers JA, Peters J, Persohn SC, McCarthy BP, Bedwell AA, Figueiredo LL, Cope ZA, Sasner M, Howell GR, Williams HM, Oblak AL, Lamb BT, Carter GW, Rizzo SJS, Territo PR. Onos KD, et al. Among authors: biesdorf c. Alzheimers Dement (N Y). 2022 Aug 23;8(1):e12329. doi: 10.1002/trc2.12329. eCollection 2022. Alzheimers Dement (N Y). 2022. PMID: 36016830 Free PMC article.
Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study.
Biesdorf C, Guan X, Siddani SR, Hoffman D, Boehm N, Medeiros BC, Doi T, de Jonge M, Rasco D, Menon RM, Polepally AR. Biesdorf C, et al. Cancer Chemother Pharmacol. 2024 Apr;93(4):329-339. doi: 10.1007/s00280-023-04613-9. Epub 2023 Nov 30. Cancer Chemother Pharmacol. 2024. PMID: 38036720 Clinical Trial.